These results suggest that combined pharmacological inhibition of TNF and IL-6 in the context of severe HDM-induced asthma may provide benefit in TGF-β-dependent lung remodeling, as compared to inhibition of these cytokines individually. The gene discussed is TNF; the disease is asthma.